PubMed Health⌕ Search

PubMed · 11724513

Current topics on cryofiltration technologies.

Abstract

In the last 40 years, therapeutic plasmapheresis techniques have been improving considerably. These include cryofiltration technologies providing novel ways of removing large amounts of cryoproteins from plasma. The concept of cryofiltration involves exposure of plasma to below core (37 degrees C) and room temperatures (25 degrees C) without freezing. It was initially used to treat diseases such as cryoglobulinemia with systemic vasculitis, rheumatoid arthritis, systemic lupus erythematosus, and ABO-incompatible transplants. There are 2 basic types of cryofiltration. The first method removes cryoproteins, namely cryoglobulins that precipitate at 4 degrees C. Several filters have been used for this procedure like the AP06M (Asahi Medical, Tokyo, Japan) with a 0.2 microm pore size, a 0.65 m2 surface area, and a cellulose diacetate (CDA) membrane. It has been used in the United States and Japan for treatment of rheumatoid arthritis and cryoglobulinemia. A major disadvantage was frequent filter plugging, which was cumbersome and it is no longer used in the United States. The G3 cryofilter (Gelman Sciences, Ann Arbor, MI, U.S.A.) with a 3 microm pore size was tried in vitro but proved inadequate by design. Currently in our institution, the cryoglobulin filter (Pall Medical, Ann Arbor, MI, U.S.A.) is used with a 4.3 microm pore size, a 0.135 m2 surface area, and an acrylic co-polymer pleat membrane. We performed over 1,200 procedures in 40 patients in the last 8 years. The second type of cryofiltration removes cryogel, which is an agglutination complex of fibrinogen, fibronectin, fibrin split products, and cold insoluble proteins with a heparin core, at temperatures between 2 and 10 degrees C. The AP06M, the AC1740 (Asahi Medical) with a 0.02 microm pore size, a 1.70 m2 surface area, and a CDA membrane, and the Evaflux-4A (Kuraray Company, Osaka, Japan) with a 0.03 microm pore size, a 2 m2 surface area, and an ethylene vinyl alcohol membrane are used to remove cryogel to treat ABO-incompatible transplants as well as rheumatoid arthritis and other previously mentioned diseases. This article will discuss each cryofiltration treatment modality.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

G A Siami, F S Siami. 2001. Current topics on cryofiltration technologies.. https://doi.org/10.1046/j.1526-0968.2001.00357.x

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Large-scale generation of mature monocyte-derived dendritic cells for clinical application in cell factories.

Dendritic cells (DC) are increasingly used for the immunotherapy of cancer. Both the induction of tumor-specific T cells and some clinical regressions have been observed in early phase I/II trials by using either DC isolated from blood, DC generated from CD34+ precursors ex vivo, and most frequently, by employing monocyte-derived DC. As DC vaccination is now awaiting phase II/III trials with larger patient collectives, it becomes increasingly important to overcome prior limitations such as the repetitive, labor-intensive generation of DC in a large number of open culture vessels. We describe here as a result of several years of optimization, in detail, a procedure that uses the so-called Nunc cell factories to process a whole apheresis product, labor- and cost-effectively in a quasi-closed system to reproducibly generate (by using GM-CSF+IL-4 followed by a maturation cocktail composed of IL-1beta+IL-6+TNF-alpha +PGE(2)) large numbers (8.32+/-3.8% of input peripheral blood mononuclear cells (PBMC)) of mature (>85% CD83+), monocyte-derived DC that can be successfully cryopreserved. Our report is based on the processing of >100 aphereses including 52 unselected aphereses in advanced melanoma patients. This allows us also to suggest meaningful quality and validation criteria. The DC generation method appears particularly promising as respective DC vaccination proved to be immunogenic in cancer patients and cell factories can readily be converted to a fully closed system by using appropriate valves, tubings, and bags.

Blood Component Removal↗

Concurrent collection of in-line filtered platelets and red blood cells by apheresis.

Multicomponent apheresis procedures offer the possibility to collect standardized blood components as compared to whole blood donations. A new program for the concurrent collection of platelets (PLTs) and red blood cells (RBCs) was evaluated in a prospective study. Apheresis donors ( n=18) underwent concurrent collection of PLTs and RBCs using the Haemonetics MCS+ blood cell separator. Aliquots of PLTs and RBCs were collected during five to six passes of the discontinuous flow procedure. The platelet product was in-line filtered during the last pass of the separation procedure. After collection, saline-adenine-glucose-mannitol (SAGM) preservative solution was automatically added to the RBCs. Thereafter, the RBCs were in-line leukodepleted by gravity filtration at room temperature. The PLTs and RBCs were subsequently stored at 22+/-2 degrees C for 5 days and 4+/-2 degrees C for 35 days, respectively. The following in vitro parameters were evaluated over the storage periods: blood cell counts, glucose, lactate, lactate dehydrogenase, pH, plasma hemoglobin, and potassium. Two ready-to-use blood components from one donor were collected in an average procedure time of 86+/-10 min; 2.47+/-0.74 x 10(11) PLTs were collected in a product volume of 232+/-43 ml. The RBC volume averaged 280+/-20 ml and the hemoglobin content was 56.8+/-2.4 g per unit. The leukocyte contamination of the platelet product was 0.44+/-0.56 x 10(5) and the residual leukocyte content of the RBC product was 0.28+/-0.02 x 10(5). Storage data showed no relevant drop in pH. Day 35 results of the RBC products showed that all of the units had less than 0.8% hemolysis. Standardized PLT and RBC products of good quality can be concurrently collected with the MCS+ blood cell separator. In vitro testing of the products collected and stored for 5 and 35 days, respectively, met the Council of Europe criteria for leukodepleted blood products.

Blood Component Removal↗